Rick Landin, Ph. D.

biostatistics, founder, precision analytics, data mining, Statics, Biometrics, Digital health, analysis, drug development, clinical, FDA, lifecycle management, life cycle management, trials, global regulatory submissions, data management, real-worlds evidence, Data science, startups

Data Mining, Endpoint Development, and Statistical Methods

President and CEO, Presagia, Inc

Dr. Landin has over 25 years of drug development experience ranging from preclinical to post-commercialization. His therapeutic areas of expertise include precision medicine, oncology, asthma and allergy, migraine, insomnia, depression, general anxiety disorder, multiple sclerosis, lupus, and rheumatoid arthritis.

During his time in the industry, Dr. Landin has established a history of building, managing and leading Biometrics organizations in large R&D (Marion Merrell Dow, Eli Lilly, Biogen), small-to-midsize-pharma (IDEC, Neurocrine), as well as pre-commercialization (Ambit, Ignyta, La Jolla Pharmaceuticals). In addition, he has served and led cross functional, multi-corporate teams, leading to regulatory submission and approval of multiple products.

Dr. Landin holds a Ph.D. is Statistics from Texas A&M University. Since graduating from Texas A&M, Dr. Landin has been committed to the practical application of statistical theory for the advancement of drug development, with successes including the following: development of the Theory of Selective Score Inflation to redesign depression studies, the creation of innovative endpoints for the measure of Sleep Maintenance, innovative data presentation of QTc data, and most recently serving as a catalyst in the development of a precision medicine toolbox based on advances in applied math/machine learning.

In 2018 Dr. Landin co-founded Presagia.AI, an advanced precision analytics company that uses predictive statistical modeling and machine learning to optimize planning, executions and inference from drug development programs.